CompletedNot Applicable

Patient Satisfaction and Safety of Miradry Treatment for Axillary Hyperhidrosis

Sweden100 participantsStarted 2020-09-04

Plain-language summary

Primary localized hyperhidrosis is a dermatological disorder that involves excessive sweat production without an underlying cause. The disease usually affects the axillae but can also involve palms, soles of the feet or face and causes major problems in many social situations with a negative impact on quality of life and mental health. In this study, the investigators want to investigate the effect of microwave therapy (MiraDry®) on self-rated sweating, quality of life and anxiety in participants with severe axillary hyperhidrosis. The study also aims to evaluate the safety (side effects) of the method and long term effects over 1 year of follow upp.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * This study will recruit participants diagnosed with primarily axillary hyperhidrosis * Informed consent is required. * HDSS 3 or 4 (the criteria used in Sweden to allow hospital-based intervention). Exclusion Criteria: Participants * who are unable to provide informed consent, * have known allergies to lidocaine, chlorhexidine, and/or epinephrine, * are pregnant, * are unable to take oral antibiotics or antiseptic washes, * have heart pacemakers or other electronic device implants, * who need supplemental oxygen, * have had axillary surgery procedures for hyperhidrosis, * with previous hidradenitis suppurativa or other local infections * had previous cancer in the treated area are not eligible to participate in this study

What they're measuring

The effectiveness of miraDry treatment

Timeframe: 1 year

Trial details

NCT IDNCT04546438

SponsorRegion Östergötland

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12-01